Landmark Approvals of 2024 | Ep. 538
New Drugs For Areas Lacking Standard of Care
Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary is as always on Thursday focused on the general market update. For the week XBI was FLAT +0% and remains GRAY at +0% for the year. Without much news yet from the young 2025 calendar year, we will spend time today on a review of 2024 new drug approvals. In 2024, the FDA set a n…
Keep reading with a 7-day free trial
Subscribe to BowTiedBiotech to keep reading this post and get 7 days of free access to the full post archives.